Event Registration - Cancer Genomics Consortium

The Cancer Genomics Consortium invites you to attend a webinar, Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing, sponsored by Oxford Nanopore Technologies on October 28, 2025.

Epigenetic alterations play a pivotal role in cancer biology, and methylation profiling has become a key tool for tumor classification and clinical decision-making. This webinar will explore how Oxford Nanopore direct DNA sequencing enables comprehensive methylation profiling in real time, without bisulfite or enzymatic conversion and no PCR amplification. Attendees will learn how this approach delivers a streamlined, integrated view of both genetic and epigenetic variation, offering faster, more complete insights from tumor DNA.

The first presentation, by Dr. Francisco Marchi (ALMA Genomics)*, will introduce the Acute Leukemia Methylome Atlas, a harmonized dataset of over 3,000 leukemia samples. Dr. Marchi will demonstrate how long-read nanopore sequencing and machine learning enable accurate AML subtype prediction and five-year survival modeling, underscoring the clinical potential of rapid, cost-effective methylation-based diagnostics for blood cancers.

The second presentation, by Dr. Skarphedinn Halldorsson (Oslo University Hospital), will highlight the application of nanopore whole-genome sequencing for rapid, comprehensive molecular profiling of CNS tumors. This approach offers a complete and efficient solution for detecting potentially diagnostically and therapeutically relevant alterations. It also enables retrospective reclassification without additional testing, potentially replacing current genomic methods in molecular neuropathology with superior completeness, cost-effectiveness, and speed.

Together, these talks will showcase how nanopore sequencing is transforming tumor methylation profiling, advancing precision oncology through speed, scalability, and completeness.
 
Speakers: 
Francisco Marchi, PhD, ALMA Genomics Inc.
Skarphedinn Halldorsson, PhD, Oslo University Hospital, Norway
Ellie Juarez, PhD, Oxford Nanopore Technologies

Learning Objectives: In this webinar you will learn how: 

1. Direct DNA sequencing enables real-time, PCR-free methylation and genetic profiling of tumors 
2. Methylation signatures can be leveraged for diagnostic and prognostic classification in leukemia
3. Rapid methylation profiling can support accurate CNS tumor classification and integration into precision oncology workflows 

---

Oxford Nanopore Technologies products are RUO. 
Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in-vitro diagnostic devices in some jurisdictions, please check individual product labelling. 
Oxford Nanopore Technologies present the materials of third parties within the user community acknowledging that those materials belong to and are the true statements and representations of those third parties. Oxford Nanopore Technologies make no endorsements of the materials shown and the statements made.